MYC amplification	Non Small Cell Lung Cancer	MYC amplification	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
MYC amplification	Small Cell Lung Cancer	MYC amplification	Small Cell Lung Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
MYC amplification	Esophageal Cancer	MYC amplification	Esophageal Cancer	ibrutinib Sensitive: C2 – Inclusion Criteria ibrutinib Sensitive : C2	ibrutinib Sensitive: C2 – Inclusion Criteria ibrutinib Sensitive : C2
MYC amplification	Melanoma	MYC amplification	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
MYC amplification	Ovarian Cancer	MYC amplification	Ovarian Cancer	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3
MYC amplification	Triple Negative Breast Cancer	MYC amplification	Triple Negative Breast Cancer	talazoparib Resistant: C3 – Early Trials talazoparib Resistant : C3	talazoparib Resistant: C3 – Early Trials talazoparib Resistant : C3
MYC amplification	Non Small Cell Lung Cancer	MYC amplification	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
MYC amplification	Ovarian Cancer	MYC amplification	Ovarian Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
MYC amplification	HER2 Positive Breast Cancer	MYC amplification	HER2 Positive Breast Cancer	trastuzumab + atezolizumab + pertuzumab Resistant: C3 – Early Trials trastuzumab + atezolizumab + pertuzumab Resistant : C3	trastuzumab + atezolizumab + pertuzumab Resistant: C3 – Early Trials trastuzumab + atezolizumab + pertuzumab Resistant : C3
MYC amplification	Squamous Cell Carcinoma of Head and Neck	MYC amplification	Squamous Cell Carcinoma of Head and Neck	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4
MYC amplification	Acute Myelogenous Leukemia	MYC amplification	Acute Myelogenous Leukemia	venetoclax Sensitive: C4 – Case Studies venetoclax Sensitive : C4	venetoclax Sensitive: C4 – Case Studies venetoclax Sensitive : C4
MYC amplification	Small Cell Lung Cancer	MYC amplification	Small Cell Lung Cancer	talazoparib + GSK525762 Sensitive: D – Preclinical talazoparib + GSK525762 Sensitive : D	talazoparib + GSK525762 Sensitive: D – Preclinical talazoparib + GSK525762 Sensitive : D

MYC amplification

Associations